pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida Closes $17.8 Million Offering

PSivida Closes $17.8 Million Offering

Today's Weak On High Volume Stock: PSivida (PSDV)

Today's Weak On High Volume Stock: PSivida (PSDV)

Trade-Ideas LLC identified pSivida (PSDV) as a weak on high relative volume candidate

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified pSivida (PSDV) as a strong on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABBV, ACHN, DBD, DFS, GBLI, IFON, JOBS, LCUT, LOJN, NTL, RAIL, STT, TTWO, UVV Downgrades: AAWW, ASPN, BCH, ECPG, ETE, GSL, LPG, LXU, MW, MYRG, NTK, PCYO, PSDV, SEB, TNGO Initiations: RWLK, TPH, VTAE Read on to get TheStreet Quant Ratings' detailed report:

PSivida Announces NDA For Medidur™ Now Planned Using Six-Month Efficacy Data From Both Phase III Trials; FDA Concurs

PSivida Announces NDA For Medidur™ Now Planned Using Six-Month Efficacy Data From Both Phase III Trials; FDA Concurs

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that the Company now plans to file a New Drug Application (NDA) for Medidur...

PSivida CEO To Present At Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

PSivida CEO To Present At Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr.

PSivida Corp. Provides Company Update And Reports Fourth Quarter And FY 2015 Results

PSivida Corp. Provides Company Update And Reports Fourth Quarter And FY 2015 Results

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth...

PSivida CEO Invited To Speak At Surfaces In BioMaterials Foundation's BioInterface 2015 Annual Symposium

PSivida CEO Invited To Speak At Surfaces In BioMaterials Foundation's BioInterface 2015 Annual Symposium

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr.

PSivida Corp Announces Fourth Quarter And Fiscal Year 2015 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Fourth Quarter And Fiscal Year 2015 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal year...

PSivida CEO To Speak At Controlled Release Society Annual Meeting Workshop In Edinburgh, Scotland, This Weekend

PSivida CEO To Speak At Controlled Release Society Annual Meeting Workshop In Edinburgh, Scotland, This Weekend

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr.

PSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study Of Medidur™ For Uveitis

PSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study Of Medidur™ For Uveitis

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive top line results from a Phase II investigator-sponsored...

PSivida Announces Top-Line Results From Investigator-Sponsored Phase II Study Of Medidur™ For Uveitis To Be Reported Next Week

PSivida Announces Top-Line Results From Investigator-Sponsored Phase II Study Of Medidur™ For Uveitis To Be Reported Next Week

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that top line results from an investigator-sponsored, Phase II study of...

PSivida CEO To Present At ISOPT Clinical Meeting In Berlin In July 2015

PSivida CEO To Present At ISOPT Clinical Meeting In Berlin In July 2015

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr.

PSivida Reports Positive IOP Safety Data In Phase III Trial Of Medidur™ For Posterior Uveitis

PSivida Reports Positive IOP Safety Data In Phase III Trial Of Medidur™ For Posterior Uveitis

pSivida Corp. (NASDAQ:PSDV); (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive safety data from its ongoing assessment of masked safety...

PSivida Announces Two Tech Evaluation Agreements With Leading Global Pharmaceutical Company

PSivida Announces Two Tech Evaluation Agreements With Leading Global Pharmaceutical Company

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treating eye diseases, today announced that it has signed two funded technology evaluation agreements with a leading...

PSivida Corp. Reports Third Quarter FY 2015 Results

PSivida Corp. Reports Third Quarter FY 2015 Results

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its third quarter ended March 31, 2015.

PSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2015...

PSivida Corp. Reports ILUVIEN® For DME Approved In Poland

PSivida Corp. Reports ILUVIEN® For DME Approved In Poland

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Office for Registration of Medicinal Products, Medical...

PSivida Corp. Completes Targeted Enrollment Of Phase III Trial Of Medidur™ For Posterior Uveitis

PSivida Corp. Completes Targeted Enrollment Of Phase III Trial Of Medidur™ For Posterior Uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the completion of the originally targeted enrollment of 120 patients...

PSivida Announces U.S. Shipments Of ILUVIEN® For DME To Start February 23

PSivida Announces U.S. Shipments Of ILUVIEN® For DME To Start February 23

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that initial nationwide shipments of ILUVIEN® for diabetic...

PSivida Corp. Reports Second Quarter FY 2015 Results

PSivida Corp. Reports Second Quarter FY 2015 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2014.